Merck Stock In Focus After Firm Announces Positive Results From RSV Antibody Trial: Retail’s Exuberant

Merck said the incidence of adverse events (AEs) and serious AEs were comparable between the clesrovimab and placebo groups, and there were no treatment or RSV-related deaths during the study.